Trial Use of Edasalonexent Not Likely to Raise COVID-19 Risk, Catabasis Reports

Trial Use of Edasalonexent Not Likely to Raise COVID-19 Risk, Catabasis Reports
0
(0)

Clinical trial data suggest that edasalonexent — a potential Duchenne muscular dystrophy (DMD) therapy — does not affect the immune system’s ability to work as it should, making it unlikely to raise a person’s COVID-19 risk, Catabasis Pharmaceuticals said.

COVID-19 is believed to pose the greatest threat to older people and those with underlying conditions. In particular, a weakened immune system and pre-existing lung conditions are thought to increase susceptibility to the viral infection.

According to recent guidelines carried by Parent Project Muscular Dystrophy (PPMD), people with DMD are at a higher risk of COVID-19 complications if they are using steroids (which weaken the immune system), and have lung and heart problems.

Edasalonexent (formerly CAT-1004) is a small molecule designed to block the activity of the NF-kappa B pathway, which is involved in the breakdown of muscle fibers. It is believed that blocking this pathway will help preserve muscle function in DMD patients.

This investigational treatment was evaluated in the Phase 2 trial MoveDMD (NCT02439216), in which boys ages 4 to 8 were given edasalonexent or a placebo. Results at 72 weeks of treatment showed preserved muscle function, slower disease progression, less inflammation, and a good safety profile. Participants who completed MoveDMD were allowed to enroll in an ongoing open-label extension study (meaning all are given edasalonexent), called GalaxyDMD (NCT03917719).

The therapy is also being evaluated in a Phase 3 clinical trial called PolarisDMD (NCT03703882), testing edasalonexent’s effectiveness and safety in about 130 boys ages 4–7. Topline results are possible later this year. Patients in PolarisDMD will also have the opportunity to join GalaxyDMD for longer-term treatment.

In a Facebook post, Catabasis said it has not found safety concerns related to COVID-19 in its clinical studies of edasalonexent. These trials, as well as long-term toxicology studies testing edasalonexent at doses that exceed those given to patients, have found no evidence of immunosuppression or a rise in infections.

The company added that no participants in either of its ongoing trials are receiving steroid therapies.

Catabasis also said it will keep monitoring the boys’ safety closely, and that health authority recommendations should be followed to reduce infection risks to boys and their families.

Duchenne UK partnered with Catabasis earlier this year, providing financial support for a one-year Phase 2 trial testing edasalonexent in non-ambulatory boys and men with DMD.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 42
José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • trials in age of Covid-19
  • real-world data in clinical trials
  • muscle cells and proteins
  • casimersen and FDA review

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?